Prescribing overview
Vetmedin treatment requires a qualifying cardiac diagnosis and disease stage.
Key prescribing checks
- A heart murmur alone is not sufficient to establish treatment eligibility. Label-defined preclinical disease involves specific cardiac findings.
- The label excludes hypertrophic cardiomyopathy, aortic stenosis and situations in which increased cardiac output is inappropriate.
- Review arrhythmias, concurrent cardiac medication and the monitoring plan. Clinical reassessment remains important despite an established diagnosis.
- Food instructions and formulation details should come from the chosen product label; conversion between a tablet and solution requires an explicit prescribing decision.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
FDA-approvedDelay of CHF in Stage B2 preclinical MMVD; management of CHF due to MMVD or DCM
B2 requires label-defined murmur/cardiomegaly criteria; not Stage A/B1, HCM or aortic stenosis.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Sensitizes cardiac myofilaments to calcium and inhibits phosphodiesterase III.
Absorption, distribution, metabolism and elimination
Animal-specific pharmacokinetic parameters were not established by the reviewed label.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Vetmedin / Vetmedin Solution
Dogs; chewable tablets and oral solution; current labels share these contraindications.
Contraindications · when not to use
- Hypertrophic cardiomyopathy, aortic stenosis, or conditions where increasing cardiac output is inappropriate; Stage A or B1 preclinical mitral valve disease.
Precautions & monitoring
- Confirm the qualifying cardiac diagnosis. Safety has not been evaluated in young, breeding, pregnant or lactating dogs or certain congenital/metabolic diseases.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Gastrointestinal upset, lethargy and arrhythmias are reported; disease progression can produce overlapping signs.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| DogsLabel-qualified B2 MMVD or CHF due to MMVD/DCMVetmedin chewable tablets | 0.5 mg/kg total daily dose Oral · Divide into two portions approximately 12 hours apart Ongoing, with reassessment | Portions need not be equal; round to nearest half tablet; CHF concurrent therapy as appropriate. Verify full dosing label ↗ |
This tablet regimen does not establish instructions for an oral solution.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Vetmedin / Vetmedin Solution
Dogs; chewable tablets and oral solution; current labels share these contraindications.
- Concurrent heart medicines have not been evaluated in Stage B2 preclinical disease.
Monitoring
Use imaging to establish eligibility; reassess cardiac status and breathing.
Client counseling
Report new coughing, rapid breathing or collapse promptly. Secure chewables against overdose.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Store according to the dispensed product label.
Brands, formulations & ingredient identity
Active ingredients
Pimobendan
Vetmedin chewable tablets and Vetmedin Solution contain pimobendan but have different formulations; document the full product and route.
Earlier Vetmedin-CA1 naming reflects a distinct historical label. Do not assume all packages share identical indications or regulatory status.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Vetmedin
- Formulation
- Oral chewable tablet
- Label / product scope
- Dogs
Use the current tablet label for its indications.
Product label / source ↗Vetmedin Solution
- Formulation
- Oral solution
- Label / product scope
- Dogs
Same ingredient; different formulation and product label.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →